Notice of Extra General Meeting in Acarix AB
The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby invited to the extra general meeting to be held on Fri...
Acarix raises approximately SEK 22 million through exercise of warrants and resolves on a directed share issue
In December 2022, Acarix AB (publ) (“Acarix” or the “Company”) carried out a rights issue of shares and warrant...
State-of-the-Art Cardiology Clinic enhances patient care with CADScor System
Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today that Abo-Auda Associates Cardiologists in Texoma, Texas ...
Acarix Awarded Business Sweden 2023 Catalyst Program Award
Acarix, a leader in acoustic and AI-based cardiac diagnostics, is pleased to announce they have been awarded the 2023 Catalyst Program ...
Announcement from Acarix’s annual general meeting
The annual general meeting 2023 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May 2023 in Stockholm and the fol...
Acarix AB (publ) publishes Interim Report, January – March 2023
2023 is off to a good startIn the first quarter of 2023 our strategy delivered important results with a breakthrough order from the lar...
Invitation to presentation of Acarix´s first quarter report
Acarix will publish its first quarter results on Thursday 11 May 2023 at 08.00 am (CEST). A live webcast will be held at 14.00 (CEST) t...
Acarix and the American College of Cardiology collaborate on first edition framework for CADScor System
New York and Washington (May 9, 2023) -- Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced today, in collaborati...
Helen Ljungdahl Round, Acarix President & CEO presents at Redeye Investor Forum
On May 4th at 14.40 Helen Ljungdahl Round, Acarix President & CEO, presents the latest developments in the company at the Redeye In...
Acarix to present at the 2023 Aktiespararna Share Day in Stockholm
Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces that the company will present at the 2023 Aktiespararna Share ...
The exercise period for Acarix warrants of series 2022:U begins today
In December 2022, Acarix AB (publ) (“Acarix” or the “Company”) carried out a rights issue of shares and warrant...
Acarix AB’s Annual Report 2022
Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announces that the Annual Report for 2022 is available as a pdf on...